Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Simon Anders
    Senior Member
    • Feb 2010
    • 995

    #16
    By the way: The effect of seeing a large count for a gene in one sample and zero counts in all other samples is quite common when working with sample derived from very few cells.

    In such cases, it is not too uncommon that one only gets maybe around a million mRNA molecules per sample, and after reverse transcription, this is down to possibly less than a hundred thousand cDNA molecules, which then go through many rounds of PCR. If one then sequences this to a depth of a few million reads per sample, i.e., much more reads than there were initial cDNA molecules, then one is bound to see most transcript molecules several times and some individual cDNA molecules, which fared especially well in the PCR, can easily produce hundreds of reads, all showing fragments of the very same mRNA molecule.

    Hence, in a setting with very low amounts of starting RNA (typically, below ~1 µg of total RNA per sample), it is quite possible to see a huge difference, say hundreds of reads in one sample and zero reads for the same gene in all other samples, and in reality, this reflects a difference of only a single lone mRNA molecule.

    See also our paper on this issue:
    Brenencke, Anders, Kim et al., Accounting for technical noise in single-cell RNA-seq experiments
    Nature Methods, 10, 1093–1095 (2013)
    doi:10.1038/nmeth.2645
    Last edited by Simon Anders; 05-23-2014, 04:15 AM.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2






      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized
      ...
      07-31-2026, 11:01 AM
    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-31-2026, 02:55 AM
    0 responses
    20 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    16 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    16 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    26 views
    0 reactions
    Last Post SEQadmin2  
    Working...